Changeflow GovPing Healthcare & Life Sciences Alembic Generic Fingolimod Hydrochloride 0.5mg ...
Priority review Rule Added Final

Alembic Generic Fingolimod Hydrochloride 0.5mg Capsule Approved

Favicon for www.accessdata.fda.gov FDA Drugs@FDA - New Applications and Actions
Published
Detected
Email

Summary

The FDA approved Alembic Pharmaceuticals' Abbreviated New Drug Application (ANDA 207974) for Fingolimod Hydrochloride 0.5mg oral capsules on April 24, 2026. The generic drug carries a therapeutic equivalence (TE) code of AB, indicating it is bioequivalent to the reference listed drug Gilenya by Novartis. Fingolimod is used to treat patients with relapsing forms of multiple sclerosis.

Published by FDA on accessdata.fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors FDA Drugs@FDA - New Applications and Actions for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 17 changes logged to date.

What changed

The FDA granted approval to Alembic Pharmaceuticals for ANDA 207974, authorizing the marketing of Fingolimod Hydrochloride 0.5mg capsules as a generic version of Novartis' Gilenya. The approval classifies the drug as AB-rated (bioequivalent) with prescription marketing status. Generic manufacturers and their distribution partners should update their product catalogs to reflect this newly available AB-rated alternative for fingolimod, which may affect pricing negotiations and formulary positioning in the MS treatment market.

Archived snapshot

Apr 28, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

*Home | *

Abbreviated New Drug Application (ANDA): 207974
Company: ALEMBIC
- Email

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription AB No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
04/24/2026 ORIG-1 Approval STANDARD Label is not available on this site.

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL; EQ 0.5MG BASE
TE Code = AB

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 207991 ACCORD HLTHCARE
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 207974 ALEMBIC
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 208004 ALKEM LABS LTD
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 207993 APOTEX
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 207983 AUROBINDO PHARMA LTD
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 207979 BIOCON LTD
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 210252 BIONPHARMA
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 208000 DR REDDYS
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 207945 EZRA VENTURES
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 207985 GLENMARK PHARMS LTD
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 207939 HEC PHARM CO LTD
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 207933 HETERO LABS LTD V
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 208003 PRINSTON INC
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 208008 TEVA PHARMS USA
FINGOLIMOD HYDROCHLORIDE FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription No AB 207994 ZYDUS PHARMS
GILENYA FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE CAPSULE;ORAL Prescription Yes AB 022527 NOVARTIS

Parties

Get daily alerts for FDA Drugs@FDA - New Applications and Actions

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Published
April 24th, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
ANDA 207974

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Generic drug approval Pharmaceutical market entry ANDA submission
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Compliance frameworks
GxP
Topics
Intellectual Property

Get alerts for this source

We'll email you when FDA Drugs@FDA - New Applications and Actions publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!